Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus R-CHOP in newly diagnosed non-GCB diffuse large B-cell lymphoma
NL-OMON47458Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) comparing Ibrutinib + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Event-free survival. Started Jun 2014; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON47458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47458.